Epkinly is an injection used for certain types of blood cancer like large B-cell lymphoma. It helps immune cells find and destroy cancer cells.
Approval Date
19-May-23
Data Exclusivity Expiry
19-May-27
Market Exclusivity Expiry
19-May-35
Commercial snapshot
Market performance & projections
Revenue ($M)
650
CAGR (%)
42.80%
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
961
2027
1,516
2028
2,095
2029
2,703
2030
3,239
2031
3,787
2032
4,354
Molecule profile
Details & specifications
Molecule
Epcoritamab-Bysp
Innovator
GENMAB AND ABBVIE
Dosage Form
Injection
Strength
4 mg/0.8 mL and 48 mg/0.8 mL
Therapeutic Category
Anticancer
Usage
To treat relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapy
Good to know
Frequently asked questions
Ready to act on this opportunity?
Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.